OR-RADISYS
26.2.2024 08:01:32 CET | Business Wire | Press release
The World Health Organization estimates that 20% of the world’s population today suffers from some degree of hearing loss. This figure is expected to increase to an estimated 25% (nearly 2.5 billion) by 2050. Over time, individuals with hearing loss tend to stop socializing – leading to impacts on friends and family members as well as increasing the risk of other health issues, including a higher likelihood of dementia. Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.
Radisys® Corporation, a global leader of open telecom solutions, today announced the availability of Engage Clarity, a unique service that enhances the quality and comprehensibility of voice calls for people with hearing challenges. With the goal to significantly enhance their quality of life and interactions, a personalized and unique service profile is activated, enabling in-line, real-time enhancements that deliver a superior experience. Engage Clarity seamlessly integrates with telecom operators' communication networks, ensuring a smooth and user-friendly implementation experience without requiring any special applications and devices. The Engage Clarity is accessible via any device through mobile voice, fixed voice, or OTT/web communication service.
With Radisys’ Engage Clarity, MNOs have a unique opportunity to offer a fully personalized wellness solution to their subscribers and meet inclusivity and societal improvement objectives. With a suggested street price per month that is less than the cost of a cup of coffee, this unique solution enhances the quality of life and improves accessibility to services for people with hearing loss. The solution benefits can be extended to anyone in consumer and business calls.
With global leadership in media processing, Radisys is uniquely positioned to deliver the benefits of Engage Clarity through service providers. “The ability to ensure the voice clarity in conversations between grandparents and grandchildren, patients and doctors, businesses and their customers – regardless of the background noise - has broad benefits to users and operators,” said Al Balasco, Head of Digital Experiences and Applications Business, Radisys. “Voice is communication’s lowest common denominator, and ensuring the highest quality experience can be life-changing for those experiencing hearing challenges.”
Radisys’ Engage Clarity addresses a critical need for people with hearing difficulties during voice calls. Clinical trials revealed high levels of user satisfaction, with 90% of users finding speech clearer and easier to hear and 74% of users reporting that calls were less tiring, highlighting the positive impact of the service on the overall communication experience for everyone, not only people with hearing difficulties.
Hearing wellness is often neglected. Compared to examining their eyes annually, people rarely take a hearing test. Radisys’ Engage Clarity offers a unique entry point for MNOs to help people manage hearing wellness by suggesting regular check-ins with the Engage hearing profile creator when they change their handset or perhaps once a year.
Experience Engage Clarity at MWC Barcelona
Hear the difference Radisys’ Engage Clarity brings. Visit Radisys at MWC Barcelona, Stand 2D50 for a demonstration, or learn more by visiting www.engagedigital.ai/clarity. To schedule a meeting with Radisys’ experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240225545999/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
